Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $329
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Alnylam Pharmaceuticals and raises the price target from $295 to $329.
November 01, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has increased its price target for Alnylam Pharmaceuticals from $295 to $329 while maintaining an Overweight rating, indicating confidence in the company's future performance.
The increase in price target from $295 to $329 by Barclays, along with the maintained Overweight rating, suggests a positive outlook for Alnylam Pharmaceuticals. This is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100